Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Total Enrollment
50 participants
Study Classification
OBSERVATIONAL
Study Start Date
2023-06-01
Study Completion Date
2026-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to better understand what happens in the brain during the dying process.
This is a prospective observational study conducted at the end of life in the ICU at VGH. At the time of withdrawal of life sustaining therapies the investigators will monitor brain blood flow and oxygenation. The investigators will also collect blood samples to measure biomarkers of brain dysfunction.
This may help us to determine when blood flow to the brain stops and when brain function ceases. This information may provide researchers and the medical community as a whole with important information as to the best timing for organ donation. This study is the first step in commencing a research program related to improving the organ donation process. Our goal is to determine how best to provide high quality organs to those who would otherwise die without an organ transplant.
This is a prospective observational study conducted at the end of life in the ICU at VGH. At the time of withdrawal of life sustaining therapies the investigators will monitor brain blood flow and oxygenation. The investigators will also collect blood samples to measure biomarkers of brain dysfunction.
This may help us to determine when blood flow to the brain stops and when brain function ceases. This information may provide researchers and the medical community as a whole with important information as to the best timing for organ donation. This study is the first step in commencing a research program related to improving the organ donation process. Our goal is to determine how best to provide high quality organs to those who would otherwise die without an organ transplant.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Characterizing the cerebrovAscular Physiology of Optimal Mean Arterial Pressure Targeted Resuscitation
NCT03609333
Cardiac Arrest
COMPLETED
NA
Non Invasive Neuromonitoring After Cardiac Arrest
NCT02575196
Cardiac Arrest
COMPLETED
Out-of-hospital Cardiac Arrest (OHCA) Biomarkers
NCT03112486
Neurological Outcome
Cardiac Arrest
Out-Of-Hospital Cardiac Arrest
+6 more
COMPLETED
Delineating Between Pathophysiologic Phenotypes of Hypoxic Ischemic Brain Injury After Cardiac Arrest
NCT05390060
Hypoxia-Ischemia, Brain
RECRUITING
NA
Study of Regional Cerebral Oxygenation and Brain Blood Volume Changes During Carotid Endarterectomy Using the NeurOS System
NCT03981757
Carotid Disease
WITHDRAWN
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
MAIN STUDY
PURPOSE The goal of this project is to characterize the cerebrovascular physiology of circulatory death during withdrawal of life sustaining measures in humans.
JUSTIFICATION Death is defined as the permanent loss of brain function following absence of cerebral blood flow (CBF). Such physiology can result from two clinical scenarios: a) absent CBF in patients with a beating heart (neurological brain death) or b) after natural circulatory arrest. In the latter scenario, eventual cessation of innate cardiac output leads to absent CBF, brain tissue oxygenation and irreversible loss of brain function. Pertinent to solid organ transplantation, death must occur prior to consideration of organ donation. In the setting of circulatory death, withdrawal of life-sustaining measures (WLSM) is undertaken and organ donation commences after the declaration of death. This process is termed controlled donation after cardiac death (DCD). Due to the scarcity of available organ donation opportunities, the emergence of DCD has provided increased access to life-saving solid organ transplants for recipients. However, challenges remain with respect to successes of DCD graft organ function and optimal recipient outcomes. Principally, the timeliness from WLSM to circulatory death declaration is crucial to graft viability with prolonged periods associated with worse graft organ ischemia, function and adverse recipient outcomes. To this extent, the determination of the precise timing of death determination during DCD is imperative to inform timely diagnosis of death and optimize retrieval of high-quality grafts for solid organ transplant recipients.
The characterization of the cerebrovascular physiology of circulatory death in humans has knowledge gaps. Current guidelines define a pulse pressure \< 5mmHg (systolic - diastolic blood pressure) using radial arterial line monitoring as the acceptable threshold for timing of circulatory death. Although pragmatic, this definition assumes that in vivo hemodynamic physiology generated by the heart (reflected by the arterial line) is simultaneously reflected in the cerebral circulation. It is well known that systemic hemodynamics do not necessarily correlate with cerebral hemodynamics during critical illness. Pathophysiologic sequelae (e.g. elevated intracranial pressure) in critically ill acutely brain injured patients who undergo WLSM suggest that cerebral perfusion may cease before systemic hemodynamics (detected by radial arterial line monitoring) deteriorate irreversibly. As such, it is plausible that cerebral perfusion ceases before a pulse pressure \< 5mmHg is achieved thereby setting the conditions by which the physiologic requirement of circulatory death is present (absent CBF) but the clinical definition has not (pulse pressure \< 5mmHg) been reached. Clinically, this scenario would expose viable graft organs to prolonged ischemia and negatively affect solid organ transplant recipient outcomes
HYPOTHESES AND AIMS
OBJECTIVES and associated HYPOTHESIS Aim 1 (Cerebral Hemodynamics): To determine the pulse pressure (measured with an in situ radial arterial catheter) at which cerebral hemodynamics cease (measured with transcranial Doppler derived middle \[MCA-Fv\] and posterior cerebral artery blood flow velocities \[PCA-Fv\]) following WLSM. The investigators hypothesize that cerebral hemodynamics will cease when the pulse pressure is \> 5mmHg.
Aim 2 (Feasibility): To measure the feasibility to conducting multimodal monitoring and data collection during the dying process in humans until circulatory arrest. Specific physiologic variables being collected during the dying process include telemetry, peripheral oximetry, mean arterial pressure monitoring, PCA-Fv \& MCA-Fv, jugular venous bulb oximetry, pulmonary artery mixed venous oximetry and regional oxygen saturation (from near infrared spectroscopy). The investigators hypothesize that feasibility will be strong and we will successfully gather \> 80% of data points for each case.
Aim 3) To evaluate relationship between mean arterial pressure (mmHg) and brain blood flow velocity (cm/sec) during the dying process in humans until circulatory arrest.
Aim 4) To evaluate relationship between mean arterial pressure (mmHg) and oxygen extraction fraction (%) and regional oxygen saturation (%) during the dying process in humans until circulatory arrest.
Aim 5: The investigate the impact of brain biomarker release during the ischemic phase of the dying process in humans until circulatory arrest. The investigators hypothesize that brain biomarker levels will increase during the dying process.
Aim 6 (Pathology): To conduct post-mortem heart and brain autopsy to contextualize and associate tissue-based injury characteristics with physiologic observations. The investigate hypothesize that brain pathology will be related to physiologic observations.
RESEARCH DESIGN This is a prospective observational study of the evaluation of the cerebrovascular physiology of circulatory death.
STATISTICAL ANALYSIS Our sample size is one of convenience. We will enroll 50 participants. Discrete variables will be summarized by frequencies and percentages. Continuous variables will be summarized by mean (SD) or median (IQR) if data are skewed.
Aim 1: The pulse pressure at which MCA-Fv and PCA-Fv cease will be summarized as a median and range across the cohort. The percentage of patients exhibiting absent CBF with a pulse pressure of \> 5mmHg will be stated as well. Sub Aim 1b: Random slope and intercepted linear mixed effects models will be used to assess relationships between cerebrovascular and cardiovascular variables during the dying process in humans until circulatory arrest.
Aim 2: The feasibility of data elements collected will be reported by percentage of data elements obtained in each case across the cohort. In each case, a dichotomous (yes/no) reported collection of the data element will be reported. The overall percentage of data elements collected will be reported for each case and across the entire cohort as a numerical measure of feasibility.
Aim 3: Relationships between select variables will be analyzed with random slope, random intercept linear mixed-effects model with continuous predictors (MAP,) as fixed factors and patient as a random factor. Cerebrovascular responses to progressive hypotension (MAP) following WLSM will be determined via random slope and random intercept linear mixed effects models with MAP or pulse pressure as a continuous predictor and patient as a random factor.
Aim 4: Wilcoxon signed-rank tests will be used to evaluate the change in brain biomarker levels during the dying process in humans until circulatory arrest.
Aim 5: Kruskal-Wallis and Dunn's post-hoc correction will be used to assess the relationship between brain pathology and continuous physiologic variables.
Sex Based Analysis: Assessing sex-related differences will encompass an exploratory analysis to inform future hypothesis generation. In our neuromonitoring patients, the proportion of patients has been approximately 60% male and 40% female. The investigators expect a similar ratio of males to females in the current study. Data will be stratified by sex, across all patients and within each study group. Further, for both study groups the investigators will assess differences between males and females by including an interaction term group\*sex into our linear mixed models.
PATHOLOGY SUB STUDY
PURPOSE To perform post-mortem pathological examination of nervous system tissue (brain and spinal cord)
HYPOTHESIS The investigators hypothesize that the brain will show histological features correlated with early cessation of blood perfusion such as abnormalities in and around small vessels and in the blood-brain barrier, tissue edema, and markers of early cellular necrosis, and that these changes will not be present, or will be present to a much lesser extent, in the spinal cord of the same individuals.
JUSTIFICATION AND OBJECTIVES Post-mortem brain and spinal cord autopsy will be obtained in patients to provide a tissue correlate and context to the neuromonitoring data. The investigators will evaluate whether two distinct areas of the central nervous system (brain and spinal cord) with different blood supply show the same degree of histopathological changes. Specifically, pathologic examination will be undertaken to provide macroscopic evaluation of the middle and posterior cerebral arteries for signs of vascular pathology (e.g. intravascular thrombi, vasoconstricted state) to provide mechanistic explanations for the anticipated results. Examination will also be undertaken in the regions of anterior and posterior circulation to assess microvascular pathology that could explain the cerebrovascular physiologic results. This will also be compared to the spinal cord which has a different blood supply from the brain. Specifically, the formalin fixed samples will be used for hematoxylin and eosin and special stains to assess for abnormalities in and around small vessels and in the blood-brain barrier, tissue edema, and markers of early cellular necrosis.
RESEARCH DESIGN This single-center prospective post-mortem pathological analysis of patients who underwent WLST will describe the pathologic characteristics of neurological injury in the neurovascular unit.
STATISTICAL ANALYSIS The pathology tissue analysis will be used to draw descriptive analyses pertaining to the macrovascular and microvascular abnormalities present on post-mortem examination. The change in the concentrations of the arterial and cerebral arterio-venous gradients of the brain biomarkers will be analyzed before WLST and immediately following circulatory death using a one-way ANOVA analysis. Comparisons between the pulse pressure at which cerebral hemodynamics, brain oxygenation and neural electrical activity cease will be conducted between patients with an antecedent acquired brain injury versus those without using a Kruskal-Wallis test.
PURPOSE The goal of this project is to characterize the cerebrovascular physiology of circulatory death during withdrawal of life sustaining measures in humans.
JUSTIFICATION Death is defined as the permanent loss of brain function following absence of cerebral blood flow (CBF). Such physiology can result from two clinical scenarios: a) absent CBF in patients with a beating heart (neurological brain death) or b) after natural circulatory arrest. In the latter scenario, eventual cessation of innate cardiac output leads to absent CBF, brain tissue oxygenation and irreversible loss of brain function. Pertinent to solid organ transplantation, death must occur prior to consideration of organ donation. In the setting of circulatory death, withdrawal of life-sustaining measures (WLSM) is undertaken and organ donation commences after the declaration of death. This process is termed controlled donation after cardiac death (DCD). Due to the scarcity of available organ donation opportunities, the emergence of DCD has provided increased access to life-saving solid organ transplants for recipients. However, challenges remain with respect to successes of DCD graft organ function and optimal recipient outcomes. Principally, the timeliness from WLSM to circulatory death declaration is crucial to graft viability with prolonged periods associated with worse graft organ ischemia, function and adverse recipient outcomes. To this extent, the determination of the precise timing of death determination during DCD is imperative to inform timely diagnosis of death and optimize retrieval of high-quality grafts for solid organ transplant recipients.
The characterization of the cerebrovascular physiology of circulatory death in humans has knowledge gaps. Current guidelines define a pulse pressure \< 5mmHg (systolic - diastolic blood pressure) using radial arterial line monitoring as the acceptable threshold for timing of circulatory death. Although pragmatic, this definition assumes that in vivo hemodynamic physiology generated by the heart (reflected by the arterial line) is simultaneously reflected in the cerebral circulation. It is well known that systemic hemodynamics do not necessarily correlate with cerebral hemodynamics during critical illness. Pathophysiologic sequelae (e.g. elevated intracranial pressure) in critically ill acutely brain injured patients who undergo WLSM suggest that cerebral perfusion may cease before systemic hemodynamics (detected by radial arterial line monitoring) deteriorate irreversibly. As such, it is plausible that cerebral perfusion ceases before a pulse pressure \< 5mmHg is achieved thereby setting the conditions by which the physiologic requirement of circulatory death is present (absent CBF) but the clinical definition has not (pulse pressure \< 5mmHg) been reached. Clinically, this scenario would expose viable graft organs to prolonged ischemia and negatively affect solid organ transplant recipient outcomes
HYPOTHESES AND AIMS
OBJECTIVES and associated HYPOTHESIS Aim 1 (Cerebral Hemodynamics): To determine the pulse pressure (measured with an in situ radial arterial catheter) at which cerebral hemodynamics cease (measured with transcranial Doppler derived middle \[MCA-Fv\] and posterior cerebral artery blood flow velocities \[PCA-Fv\]) following WLSM. The investigators hypothesize that cerebral hemodynamics will cease when the pulse pressure is \> 5mmHg.
Aim 2 (Feasibility): To measure the feasibility to conducting multimodal monitoring and data collection during the dying process in humans until circulatory arrest. Specific physiologic variables being collected during the dying process include telemetry, peripheral oximetry, mean arterial pressure monitoring, PCA-Fv \& MCA-Fv, jugular venous bulb oximetry, pulmonary artery mixed venous oximetry and regional oxygen saturation (from near infrared spectroscopy). The investigators hypothesize that feasibility will be strong and we will successfully gather \> 80% of data points for each case.
Aim 3) To evaluate relationship between mean arterial pressure (mmHg) and brain blood flow velocity (cm/sec) during the dying process in humans until circulatory arrest.
Aim 4) To evaluate relationship between mean arterial pressure (mmHg) and oxygen extraction fraction (%) and regional oxygen saturation (%) during the dying process in humans until circulatory arrest.
Aim 5: The investigate the impact of brain biomarker release during the ischemic phase of the dying process in humans until circulatory arrest. The investigators hypothesize that brain biomarker levels will increase during the dying process.
Aim 6 (Pathology): To conduct post-mortem heart and brain autopsy to contextualize and associate tissue-based injury characteristics with physiologic observations. The investigate hypothesize that brain pathology will be related to physiologic observations.
RESEARCH DESIGN This is a prospective observational study of the evaluation of the cerebrovascular physiology of circulatory death.
STATISTICAL ANALYSIS Our sample size is one of convenience. We will enroll 50 participants. Discrete variables will be summarized by frequencies and percentages. Continuous variables will be summarized by mean (SD) or median (IQR) if data are skewed.
Aim 1: The pulse pressure at which MCA-Fv and PCA-Fv cease will be summarized as a median and range across the cohort. The percentage of patients exhibiting absent CBF with a pulse pressure of \> 5mmHg will be stated as well. Sub Aim 1b: Random slope and intercepted linear mixed effects models will be used to assess relationships between cerebrovascular and cardiovascular variables during the dying process in humans until circulatory arrest.
Aim 2: The feasibility of data elements collected will be reported by percentage of data elements obtained in each case across the cohort. In each case, a dichotomous (yes/no) reported collection of the data element will be reported. The overall percentage of data elements collected will be reported for each case and across the entire cohort as a numerical measure of feasibility.
Aim 3: Relationships between select variables will be analyzed with random slope, random intercept linear mixed-effects model with continuous predictors (MAP,) as fixed factors and patient as a random factor. Cerebrovascular responses to progressive hypotension (MAP) following WLSM will be determined via random slope and random intercept linear mixed effects models with MAP or pulse pressure as a continuous predictor and patient as a random factor.
Aim 4: Wilcoxon signed-rank tests will be used to evaluate the change in brain biomarker levels during the dying process in humans until circulatory arrest.
Aim 5: Kruskal-Wallis and Dunn's post-hoc correction will be used to assess the relationship between brain pathology and continuous physiologic variables.
Sex Based Analysis: Assessing sex-related differences will encompass an exploratory analysis to inform future hypothesis generation. In our neuromonitoring patients, the proportion of patients has been approximately 60% male and 40% female. The investigators expect a similar ratio of males to females in the current study. Data will be stratified by sex, across all patients and within each study group. Further, for both study groups the investigators will assess differences between males and females by including an interaction term group\*sex into our linear mixed models.
PATHOLOGY SUB STUDY
PURPOSE To perform post-mortem pathological examination of nervous system tissue (brain and spinal cord)
HYPOTHESIS The investigators hypothesize that the brain will show histological features correlated with early cessation of blood perfusion such as abnormalities in and around small vessels and in the blood-brain barrier, tissue edema, and markers of early cellular necrosis, and that these changes will not be present, or will be present to a much lesser extent, in the spinal cord of the same individuals.
JUSTIFICATION AND OBJECTIVES Post-mortem brain and spinal cord autopsy will be obtained in patients to provide a tissue correlate and context to the neuromonitoring data. The investigators will evaluate whether two distinct areas of the central nervous system (brain and spinal cord) with different blood supply show the same degree of histopathological changes. Specifically, pathologic examination will be undertaken to provide macroscopic evaluation of the middle and posterior cerebral arteries for signs of vascular pathology (e.g. intravascular thrombi, vasoconstricted state) to provide mechanistic explanations for the anticipated results. Examination will also be undertaken in the regions of anterior and posterior circulation to assess microvascular pathology that could explain the cerebrovascular physiologic results. This will also be compared to the spinal cord which has a different blood supply from the brain. Specifically, the formalin fixed samples will be used for hematoxylin and eosin and special stains to assess for abnormalities in and around small vessels and in the blood-brain barrier, tissue edema, and markers of early cellular necrosis.
RESEARCH DESIGN This single-center prospective post-mortem pathological analysis of patients who underwent WLST will describe the pathologic characteristics of neurological injury in the neurovascular unit.
STATISTICAL ANALYSIS The pathology tissue analysis will be used to draw descriptive analyses pertaining to the macrovascular and microvascular abnormalities present on post-mortem examination. The change in the concentrations of the arterial and cerebral arterio-venous gradients of the brain biomarkers will be analyzed before WLST and immediately following circulatory death using a one-way ANOVA analysis. Comparisons between the pulse pressure at which cerebral hemodynamics, brain oxygenation and neural electrical activity cease will be conducted between patients with an antecedent acquired brain injury versus those without using a Kruskal-Wallis test.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Circulatory Arrest
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Neuromonitoring
Multimodal Neuromonitoring:
Transcranial Doppler - middle cerebral artery blood flow velocity Jugular venous bulb oximetry - hemoglobin oxygen saturation at the jugular venous bulb Arterial blood pressure monitoring - mean arterial, systolic and diastolic pressure monitoring at the radial artery via an in situ radial arterial line catheter Pulmonary artery catheter - to measure continuous cardiac output and mixed venous oxygen saturation Near infrared spectroscopy - to measure regional cerebral saturation of oxygen
Intervention Type
DEVICE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* a) Age \> 18 years
* b) anticipated withdrawal of life-sustaining measures (WLSM) within the next 24 hours
* b) anticipated withdrawal of life-sustaining measures (WLSM) within the next 24 hours
Exclusion Criteria
* No in-situ arterial line
* No legal authorized representative
* Neurological brain death declared
* No legal authorized representative
* Neurological brain death declared
Minimum Eligible Age
19 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of British Columbia
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Myp Sekhon
Principal Investigator
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mypinder S Sekhon, MD PhD
Role: PRINCIPAL_INVESTIGATOR
University of British Columbia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vancouver General Hospital
Vancouver, British Columbia, Canada
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Canada
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Bird JD, Hornby L, Hirsch-Reinshagen V, Allen CP, Isac G, Gooderham PA, Shemie SD, Dhanani S, Thiara S, Stukas S, Grey R, Foster DA, Maier LE, LeBlanc AE, Kanji HD, Morelli TF, Agbay AM, Wellington CL, Chahal D, Belanger EC, Ren H, Mattu PS, Su S, Hrazdil CT, Percy J, Sangha P, Plewes LV, Sweet DD, Romano KR, Vu EN, Chittock DR, Dhingra VK, Henderson WR, Garraway NR, Morad Hameed S, Finlayson GN, MacLeod DB, Gibbons TD, Ainslie PN, Hoiland RL, Griesdale DE, Ronco JJ, Sekhon MS. Characterizing the physiology of circulatory arrest in humans. Nat Med. 2025 Oct;31(10):3542-3552. doi: 10.1038/s41591-025-03889-z. Epub 2025 Oct 16.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H23-00172
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Assessment of the Relationship Between Cerebral Blood Flow and Heart Rate
NCT04391465
RECRUITING
NA
Cerebral Oxygenation and Neurological Outcomes FOllowing CriticAL Illness-2
NCT03141619
RECRUITING
Cerebral Circulation in Critically Ill Children
NCT03731104
COMPLETED
Evaluation of Muscle StO2 as a Prognostic Factor After Out of Hospital Cardiac Arrest
NCT01073098
UNKNOWN
NA
Assessment of Stroke Volume and Cardiac Output in Response to Varying Heart Rates
NCT03446326
RECRUITING
NA
Regional Cerebral Oxygenation and Brain Blood Volume During Cardiac Surgery Using the NeurOS System
NCT03969836
COMPLETED
Automated Chest Physiotherapy to Improve Outcomes in Neuro
NCT00571623
COMPLETED
Cerebral Oxygenation in Cardiac Arrest and Hypothermia
NCT01531426
COMPLETED
Non-invasive Neurological Evaluation During CPR
NCT02684955
COMPLETED
Carotid Ultrasound Under Pulsed-wave Doppler Mode to Check the Pulse in Cardiopulmonary Arrest Patients.
NCT04790396
ACTIVE_NOT_RECRUITING
Definition of Hemodynamic Thresholds in Out-of-Hospital Cardiac Arrest
NCT03172468
WITHDRAWN
Monitoring of Cerebral Blood Flow in Patients on Extracorporeal Membrane Oxygenation
NCT05303363
RECRUITING
Cerebral Oximetric Monitoring of the Posterior Circulation
NCT00751712
COMPLETED
Special Imaging Technique to Aid in the Diagnosis of Patients in Coma After Cardiac Arrest
NCT02102945
COMPLETED
NA
Transitions Between Clinical Circulatory States After Out-of-hospital Cardiac Arrest
NCT02648061
COMPLETED
Cerebral Oxygenation and Neurological Outcomes FOllowing CriticAL Illness
NCT02344043
COMPLETED
Pulse Study: Peripheral Use of Low-dose Vasopressors for Safety and Efficacy in the Intensive Care Unit
NCT06920173
RECRUITING
PHASE2
Intensive Monitoring of Brain Injured Patients
NCT00163774
COMPLETED
NA
Monitoring After Cardiac Arrest: Electroencephalogram and Cerebral Oximetry in Predicting Outcome
NCT06460480
COMPLETED
Bedside Monitoring of Cerebral Energy State During the Peri-cardiac Arrest Period
NCT03095742
COMPLETED
NA
Arterial Blood Pressure and Cardiac Arrest
NCT06443567
WITHDRAWN
Validation of Respiration Rate Algorithms
NCT01472133
COMPLETED
Assessment of Brain Damage Using Monitoring of Cerebral Oximetry Dynamics in Patients After Cardiac Arrest
NCT06776302
RECRUITING
NA
Neurologic Physiology After Removal of Therapy (NeuPaRT)
NCT05306327
RECRUITING